Understanding how different cancer cell types in pancreatic cancer respond to radiation
Cellular phenotypic heterogeneity and resistance to radiotherapy in pancreatic adenocarcinoma
This study is looking at how different types of cancer cells in pancreatic cancer respond to radiation therapy, with the hope of finding better ways to help patients get more effective treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10918091 on NIH RePORTER |
What this research studies
This research investigates the diverse characteristics of cancer cells in pancreatic adenocarcinoma and how these differences affect their response to radiation therapy. By examining the microenvironments within tumors, the study aims to identify mechanisms that lead to resistance against treatment. The approach involves using pancreatic tumor models to explore how certain cancer cell subsets can influence the behavior of others, potentially leading to improved therapeutic strategies for patients. The ultimate goal is to enhance the effectiveness of radiation therapy for pancreatic cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with pancreatic ductal adenocarcinoma who are undergoing or considering radiation therapy.
Not a fit: Patients with other types of cancer or those who are not receiving radiation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective radiation treatments for pancreatic cancer, improving patient outcomes.
How similar studies have performed: Previous research has shown promise in understanding cancer cell heterogeneity and its impact on treatment resistance, suggesting that this approach could yield valuable insights.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Pitter, Kenneth L — Ohio State University
- Study coordinator: Pitter, Kenneth L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.